Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focusing on rare respiratory diseases, reported its financial results for the second quarter ending June 30, 2025. The company announced a net loss of $30.4 million for the period, compared to a net loss of $22.2 million in the same quarter of 2024. Research and development expenses saw an increase of $3.1 million, or 17.8%, totaling $20.8 million for the quarter. This rise was largely attributed to activities related to the company's MOLBREEVI program, including $3.3 million in costs related to Chemistry, Manufacturing, and Controls, and $1.1 million for Regulatory Affairs and Quality Assurance, partially offset by a $1.3 million reduction in clinical costs. Savara provided a business update indicating progress in their collaboration with Fujifilm as their drug substance manufacturer. Following a recent meeting with the FDA, Savara plans to resubmit the Biologics License Application $(BLA.AU)$ in December, with the finalization of the analytical data package expected early in the fourth quarter. The company is focused on addressing the unmet medical need for treating autoimmune PAP, a rare lung disease, with their MOLBREEVI program.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.